Shots:
- The EC has approved Conexxence & Bomyntra, biosimilar versions of Prolia & Xgeva (denosumab)
- Approval covers all indications of the reference products incl. osteoporosis in postmenopausal women & men at high risk of fracture, SRE prevention in adults with bone-involved malignancies, giant cell tumors of bone & treatment-related bone loss
- Additionally, Fresenius & Amgen reached a global settlement in Mar 2025, allowing the US launch of these biosimilars in mid-2025 & their European launch in late H2’25
Ref: Fresenius| Image: Fresenius| Press Release
Related News:- Samsung Bioepis Collaborates with Harrow to Commercialize its Ophthalmology Biosimilars in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
